person · Reporting owner

Detheux Michel

Disclosed activity across 2 companies

Tapewire entity: 38789
SEC CIK: 0001816196

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Vor Biopharma Inc.VOR · Entity 4763	Director	June 11, 2026	June 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Vor Biopharma Inc.

Report date June 11, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10	Direct	57,162	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 57,162 · Balance 57,162 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

iTeos Therapeutics, Inc.

Report date August 29, 2025 · Filed August 29, 2025

Section 16 reporting ended · disclosed 2025-08-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-08-29 transaction · row 1 1 source row Row 1 · 2025-08-29 · Other · Disposed 153,903 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes. F2: The amount reported in Column 4 includes 108,875 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or F3: (Continued from footnote 2) within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR.
Common StockSEC Table I · non-derivative	IndirectBy MG3A	Reported balance After 2025-08-29 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-08-29 · Other · Disposed 94,027 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes. F4: MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.05	Direct	Reported balance After 2025-08-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-08-29 · Disposition to issuer · Disposed 14,185 · Balance 0 F5: Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full. F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.05	Direct	Reported balance After 2025-08-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-08-29 · Disposition to issuer · Disposed 444,815 · Balance 0 F5: Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full. F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24	Direct	Reported balance After 2025-08-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-08-29 · Disposition to issuer · Disposed 94,336 · Balance 0 F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24	Direct	Reported balance After 2025-08-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-08-29 · Disposition to issuer · Disposed 50,128 · Balance 0 F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16	Direct	Reported balance After 2025-08-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-08-29 · Disposition to issuer · Disposed 17,544 · Balance 0 F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24	IndirectBy MG3A	Reported balance After 2025-08-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-08-29 · Disposition to issuer · Disposed 185,000 · Balance 0 F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option. F4: MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.16	IndirectBy MG3A	Reported balance After 2025-08-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-08-29 · Disposition to issuer · Disposed 52,700 · Balance 0 F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option. F4: MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the "Cash Amount"); plus (ii) one non-transferable contractual contingent value right per share (each, a "CVR"), without interest and subject to applicable withholding of taxes.

F2: The amount reported in Column 4 includes 108,875 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the "Committee") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or

F3: (Continued from footnote 2) within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR.

F4: MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.

F5: Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full.

F6: In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 05, 2023 Filed Dec 7, 2023 20:20 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0000950170-23-068900 · ownership.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,903 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. All of the shares of common stock underlying such RSUs will vest on December 5, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Amount of Securities Beneficially Owned includes 1,445 and 1,195 shares purchased under the Company's 2020 Employee Stock Purchase Plan on November 30, 2022 and May 31, 2023, respectively. Read SEC document
March 09, 2023 Filed Mar 10, 2023 19:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	254,997	$0.00 Strike: $16.66	$0.00	Disclosure SEC source: 0001209191-23-018013 · doc4.xml · derivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 254,997 Underlying: Common Stock · 254,997 shares Expires 2033-03-09 F2 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F1 · derivative.exercise_date: This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer. F2 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
March 09, 2023 Filed Mar 10, 2023 19:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	254,997	$0.00 Strike: $16.66	$0.00	Disclosure SEC source: 0001209191-23-018013 · doc4.xml · derivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,003 Underlying: Common Stock · 254,997 shares Expires 2033-03-09 F2 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F1 · derivative.exercise_date: This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer. Read SEC document
March 09, 2023 Filed Mar 10, 2023 19:51 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	346,000	$0.00 Strike: $16.66	$0.00	Disclosure SEC source: 0001209191-23-018013 · doc4.xml · derivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,000 Underlying: Common Stock · 346,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer. Read SEC document
April 18, 2022 Filed Apr 19, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionStock Option (Right to Buy) · Derivative	11,500	$0.00 Strike: $4.23	$0.00	Disclosure SEC source: 0001209191-22-024859 · doc4.xml · derivative · entry 4 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,464 Underlying: Common Stock · 11,500 shares Expires 2030-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
April 18, 2022 Filed Apr 19, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	33	$32.64	$1,077.12	Disclosure SEC source: 0001209191-22-024859 · doc4.xml · nonDerivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,263 Read SEC document
April 18, 2022 Filed Apr 19, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,467	$31.87	$365,453.29	Disclosure SEC source: 0001209191-22-024859 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 18, 2022 Filed Apr 19, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionCommon Stock	11,500	$4.23	$48,645.00	Disclosure SEC source: 0001209191-22-024859 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2022 Filed Mar 10, 2023 19:50 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	264,375	$0.00 Strike: $36.21	$0.00	Disclosure SEC source: 0001209191-23-018012 · doc5.xml · derivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 264,375 Underlying: Common Stock · 264,375 shares Expires 2032-03-11 F1 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F2 · derivative.exercise_date: This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer. Read SEC document
April 15, 2022 Filed Mar 10, 2023 19:50 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	264,375	$0.00 Strike: $36.21	$0.00	Disclosure SEC source: 0001209191-23-018012 · doc5.xml · derivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,125 Underlying: Common Stock · 264,375 shares Expires 2032-03-11 F1 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F2 · derivative.exercise_date: This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer. Read SEC document
March 22, 2022 Filed Mar 22, 2022 20:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,548	$36.51	$56,517.48	Disclosure SEC source: 0001209191-22-020649 · doc4.xml · nonDerivative · entry 4 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,263 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.06 to $36.85, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 22, 2022 Filed Mar 22, 2022 20:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,159	$35.22	$40,819.98	Disclosure SEC source: 0001209191-22-020649 · doc4.xml · nonDerivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.92 to $35.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 22, 2022 Filed Mar 22, 2022 20:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	9,908	$34.11	$337,961.88	Disclosure SEC source: 0001209191-22-020649 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,970 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.92 to $34.9, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 22, 2022 Filed Mar 22, 2022 20:05 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	5,822	$33.44	$194,687.68	Disclosure SEC source: 0001209191-22-020649 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,878 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 11, 2022 Filed Mar 14, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantStock Option (Right to Buy) · Derivative	352,500	$0.00 Strike: $36.21	$0.00	Disclosure SEC source: 0001209191-22-018667 · doc4.xml · derivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,500 Underlying: Common Stock · 352,500 shares Expires 2032-03-11 F2 · derivative.exercise_date: This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer. Read SEC document
March 11, 2022 Filed Mar 14, 2022 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-018667 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,700 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying such RSUs will vest on the first anniversary of the grant date, and the remaining shares subject to the RSUs will vest on a quarterly basis thereafter in equal installments over the following twelve (12) quarters, subject to the Reporting Person's continued service to the Issuer. Read SEC document
February 23, 2022 Filed Feb 24, 2022 20:00 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	544	$35.32	$19,214.08	Disclosure SEC source: 0001209191-22-012880 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,700 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.51, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 23, 2022 Filed Feb 24, 2022 20:00 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	13,956	$34.30	$478,690.80	Disclosure SEC source: 0001209191-22-012880 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,244 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.82 to $34.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 25, 2022 Filed Jan 26, 2022 19:53 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	4,412	$36.21	$159,758.52	Disclosure SEC source: 0001209191-22-005118 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,200 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.75, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 25, 2022 Filed Jan 26, 2022 19:53 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	10,088	$35.45	$357,619.60	Disclosure SEC source: 0001209191-22-005118 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,612 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.91, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionStock Option (Right to Buy) · Derivative	1,663	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 23 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 1,663 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F9 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	9,493	$45.37	$430,697.41	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 10 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,700 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	5,007	$44.62	$223,412.34	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 9 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,193 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	149	$44.92	$6,693.08	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 8 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	1,514	$44.31	$67,085.34	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 7 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,349 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 22, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionCommon Stock	1,663	$4.30	$7,150.90	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 6 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. Read SEC document
December 21, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionStock Option (Right to Buy) · Derivative	19,226	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 22 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,663 Underlying: Common Stock · 19,226 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F9 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 21, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	5,580	$45.06	$251,434.80	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 5 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 21, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	13,646	$44.15	$602,470.90	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 4 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,780 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 21, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionCommon Stock	19,226	$4.30	$82,671.80	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. Read SEC document
December 20, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionStock Option (Right to Buy) · Derivative	9,111	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 21 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,889 Underlying: Common Stock · 9,111 shares Expires 2025-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F9 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 20, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	9,111	$43.94	$400,337.34	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 20, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionCommon Stock	9,111	$4.30	$39,177.30	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	106,200	$0.00 Strike: $41.58	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 20 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 106,200 Underlying: Common Stock · 106,200 shares Expires 2031-03-01 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F13 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. F8 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	106,200	$0.00 Strike: $41.58	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 19 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,800 Underlying: Common Stock · 144,000 shares Expires 2031-03-01 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F13 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	776,600	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 18 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 776,600 Underlying: Common Stock · 776,600 shares Expires 2030-07-23 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F12 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. F8 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	776,600	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 17 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,824 Underlying: Common Stock · 1,035,424 shares Expires 2030-07-23 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F12 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	52,700	$0.00 Strike: $6.15	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 16 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 52,700 Underlying: Common Stock · 52,700 shares Expires 2030-06-18 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F11 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. F8 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	52,700	$0.00 Strike: $6.15	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 15 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,544 Underlying: Common Stock · 70,244 shares Expires 2030-06-18 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F11 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	185,000	$0.00 Strike: $4.23	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 14 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2030-05-01 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F10 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. F8 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	185,000	$0.00 Strike: $4.23	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 13 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,964 Underlying: Common Stock · 340,964 shares Expires 2030-05-01 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F10 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	313,442	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 12 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By MG3A Disclosed balance after: 313,442 Underlying: Common Stock · 313,442 shares Expires 2025-06-11 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F9 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. F8 · ownership.nature: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. Read SEC document
December 02, 2021 Filed Dec 22, 2021 20:01 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	GiftStock Option (Right to Buy) · Derivative	313,442	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001209191-21-070996 · doc4.xml · derivative · entry 11 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 403,442 shares Expires 2025-06-11 F8 · kind: The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager. F9 · derivative.exercise_date: One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date. Read SEC document
November 23, 2021 Filed Nov 24, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	14,500	$36.08	$523,160.00	Disclosure SEC source: 0001209191-21-066884 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 22, 2021 Filed Nov 24, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionStock Option (right to buy) · Derivative	16,263	$0.00 Strike: $12.45	$0.00	Disclosure SEC source: 0001209191-21-066884 · doc4.xml · derivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,263 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. F4 · derivative.exercise_date: The option is fully vested. Read SEC document
November 22, 2021 Filed Nov 24, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	Exercise / conversionCommon Stock	16,263	$12.45	$202,474.35	Disclosure SEC source: 0001209191-21-066884 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document
November 03, 2021 Filed Nov 3, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	6,085	$28.89	$175,777.40	Disclosure SEC source: 0001209191-21-062843 · doc4.xml · nonDerivative · entry 3 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.245 to $29.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 02, 2021 Filed Nov 3, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	14,391	$28.42	$408,920.27	Disclosure SEC source: 0001209191-21-062843 · doc4.xml · nonDerivative · entry 2 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,522 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 01, 2021 Filed Nov 3, 2021 19:59 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	81	$28.00	$2,268.00	Disclosure SEC source: 0001209191-21-062843 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,913 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. Read SEC document
October 21, 2021 Filed Oct 25, 2021 20:00 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	196	$28.00	$5,488.02	Disclosure SEC source: 0001209191-21-061569 · doc4.xml · nonDerivative · entry 1 Detheux Michel · CIK 0001816196 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,994 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.005, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.